Last reviewed · How we verify
T89 high dose
T89 is a traditional Chinese medicine compound that improves myocardial energy metabolism and reduces ischemic injury in cardiovascular disease.
T89 is a traditional Chinese medicine compound that improves myocardial energy metabolism and reduces ischemic injury in cardiovascular disease. Used for Chronic stable angina pectoris, Acute coronary syndrome, Heart failure.
At a glance
| Generic name | T89 high dose |
|---|---|
| Also known as | Dantonic®, Compound Danshen Dripping Pills, Salvtonic® |
| Sponsor | Tasly Pharmaceuticals, Inc. |
| Drug class | Traditional Chinese medicine compound / Herbal extract |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
T89 (Danshen dripping pill) contains multiple active components that enhance ATP production in cardiac mitochondria, improve coronary blood flow, and reduce oxidative stress and apoptosis in ischemic myocardium. The formulation works through multiple pathways including mitochondrial protection, anti-inflammatory effects, and improvement of cardiac contractility.
Approved indications
- Chronic stable angina pectoris
- Acute coronary syndrome
- Heart failure
Common side effects
- Gastrointestinal disturbance
- Dizziness
- Headache
Key clinical trials
- Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina (PHASE3)
- Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS) (PHASE3)
- Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS) (PHASE2)
- Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina (PHASE3)
- Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T89 high dose CI brief — competitive landscape report
- T89 high dose updates RSS · CI watch RSS
- Tasly Pharmaceuticals, Inc. portfolio CI